Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 115Gliosarcoma 53Brain Neoplasms 53Glioma 47Central Nervous System Neoplasms 30Astrocytoma 29Melanoma 26Oligodendroglioma 14Neuroblastoma 10Neoplasm Metastasis 9Recurrence 7Ependymoma 7Sarcoma 6Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Skin Neoplasms 5Sarcoma, Ewing 5Lymphoma 5Breast Neoplasms 5Spinal Cord Neoplasms 4Somatostatinoma 4Neuroectodermal Tumors, Primitive, Peripheral 4Medulloblastoma 4Colorectal Neoplasms 4Small Cell Lung Carcinoma 3Lung Neoplasms 3Gastrinoma 3Carcinoma, Islet Cell 3Uveal Melanoma 2Rhabdomyosarcoma 2

Interventions

Bevacizumab 3Temozolomide 2Sorafenib 2pembrolizumab 1Valproic Acid 1Therapeutics 1Sildenafil Citrate 1Radiosurgery 1Irinotecan 1Equipment and Supplies 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Neurologic Manifestations × Temozolomide × Clear all
NCT02343549 2022-11-03

A Phase II Study of Optune (NovoTTF) in Combination With Bevacizumab (BEV) and Temozolomide (TMZ) in Patients With Newly Diagnosed Unresectable Glioblastoma (GBM)

Wake Forest University Health Sciences

Phase 2 Terminated
13 enrolled 23 charts
CNS

Brain Neoplasms, Neurologic Manifestations

NCT01120639 2021-08-06

Tx-Treatment

Stanford University

Phase 1/2 Completed
30 enrolled 19 charts
CNS

Brain Neoplasms, Glioblastoma, Neurologic Manifestations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡